Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer

Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials

(2013) Fausto Petrelli et al.   BREAST CANCER RESEARCH AND TREATMENT

Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial

(2013) Paul E. Goss et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer

(2012) Nathan W. D. Lamond et al.   BREAST CANCER RESEARCH AND TREATMENT

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

Model Parameter Estimation and Uncertainty Analysis

(2012) Andrew H. Briggs et al.   MEDICAL DECISION MAKING

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

(2011) Judith M. Bliss et al.   JOURNAL OF CLINICAL ONCOLOGY

Aromatase Inhibitors (AIs) Versus Not (Placebo/Observation) as Late Extended Adjuvant Therapy for Postmenopausal Women with Early Stage Breast Cancer (BC): Overviews of Randomized Trials of AIs after ∼ 5 Years of Tamoxifen.

(2010) P. Goss et al.   CANCER RESEARCH

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

(2010) Jack Cuzick et al.   LANCET ONCOLOGY